Head-To-Head Survey: Kadmon (KDMN) and Syndax Pharmaceuticals (SNDX)

Kadmon (NYSE: KDMN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Earnings & Valuation

This table compares Kadmon and Syndax Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kadmon $26.06 million 10.74 -$208.75 million ($1.75) -2.03
Syndax Pharmaceuticals $1.22 million 168.53 -$44.47 million ($2.83) -2.98

Syndax Pharmaceuticals has lower revenue, but higher earnings than Kadmon. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kadmon, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

51.9% of Kadmon shares are owned by institutional investors. Comparatively, 61.7% of Syndax Pharmaceuticals shares are owned by institutional investors. 8.4% of Kadmon shares are owned by company insiders. Comparatively, 24.1% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Kadmon and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kadmon -555.91% N/A -124.91%
Syndax Pharmaceuticals -4,304.34% -57.90% -45.09%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Kadmon and Syndax Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kadmon 1 1 2 0 2.25
Syndax Pharmaceuticals 0 0 8 0 3.00

Kadmon currently has a consensus target price of $9.75, indicating a potential upside of 173.88%. Syndax Pharmaceuticals has a consensus target price of $24.29, indicating a potential upside of 188.09%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Kadmon.


Syndax Pharmaceuticals beats Kadmon on 8 of the 13 factors compared between the two stocks.

About Kadmon

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit